Physician profile
Farah K Malick
NPI 1891819801
$16,676.69
in general payments reported to CMS, 2019-2025
33 companies · $3,747 in 2025
The $3,747 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,946 · 2020: $1,007 · 2021: $1,407 · 2022: $3,176 · 2023: $2,623 · 2024: $2,769 · 2025: $3,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,543 · Education: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,542.78 |
| Education | $596.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,218.35 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,669.64 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,569.01 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $1,425.99 | 2019-2025 | Dupixent |
| Zerigo Health, INC. | $1,350.00 | 2022 | |
| Ucb, INC. | $812.36 | 2020-2025 | Bimzelx |
| Genzyme Corporation | $764.12 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $673.32 | 2019-2025 | |
| Incyte Corporation | $652.48 | 2021-2024 | Opzelura |
| Lilly USA, LLC | $621.62 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Leo Pharma INC. | $597.30 | 2022-2025 | Anzupgo, Adbry |
| Pfizer INC. | $542.87 | 2019-2025 | |
| Galderma Laboratories, L.P. | $483.13 | 2024-2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $416.75 | 2019-2022 | |
| Almirall LLC | $388.60 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $381.58 | 2022-2024 | Sotyktu |
| Prugen, INC. Pharmaceuticals | $363.13 | 2020-2021 | |
| Glaxosmithkline, LLC. | $249.48 | 2023 | Nucala |
| Amgen INC. | $236.62 | 2023-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $200.13 | 2019-2025 | Cabtreo |
| Arcutis Biotherapeutics, INC. | $156.08 | 2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $154.49 | 2020-2021 | |
| Celgene Corporation | $124.98 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $110.88 | 2023 | Evusheld |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.80 | 2023 | Trulance, Xifaxan |
| Orapharma, A Division of Bausch Health US, LLC | $97.07 | 2024 | Arestin |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Organon LLC | $54.22 | 2025 | Vtama |
| Dermavant Sciences, INC. | $39.50 | 2023 | Vtama |
| Cipher Pharmaceuticals US LLC | $39.16 | 2025 | Natroba, Spinosad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.92 | 2023 | Spevigo |
| Verrica Pharmaceuticals INC. | $33.52 | 2024 | Ycanth |
| Epi Health, LLC | $21.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farah Malick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.